Neuren Pharmaceuticals Ltd has released a press release.
Q2 2023 quarterly activity and cash flow report
Filed with ASX ·
6ix hasn’t read this filing yet.
Neuren Pharmaceuticals Limited on 6ix
Earlier from Neuren Pharmaceuticals
- Neuren receives US$100m for expanded DAYBUE agreement
- Neuren and Acadia expand global partnership for trofinetide
- Neuren completes enrolment in Phelan-McDermid Phase 2 trial
- Neuren opens first site in US for Prader-Willi Phase 2 trial
- Neuren receives US$40m milestone payment
Later from Neuren Pharmaceuticals
- S&P DJI Announces September 2023 Quarterly Rebalance
- Q3 2023 quarterly activity and cash flow report
- DAYBUE net sales US$66.9 million in Q3 2023
- Neuren completes enrolment in Pitt Hopkins Phase 2 trial
- P2 trial shows significant improvements in Phelan-McDermid
Follow Neuren Pharmaceuticals into a list and get an email when it puts out news.
Follow Neuren Pharmaceuticals